Asad Haider Analyst PerformanceAnalyst at The Goldman Sachs GroupAsad Haider is a stock analyst at The Goldman Sachs Group in the medical sector, covering 11 publicly traded companies. Over the past year, Asad Haider has issued 17 stock ratings, including buy, hold, and sell recommendations. While full access to Asad Haider's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Asad Haider's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings24 Last 6 YearsBuy Recommendations45.83% 11 Buy RatingsCompanies Covered11 Unique Companies Ratings Distribution24RatingsDistribution of strong buy, buy, hold, and sell ratings by Asad Haider.RatingPercentageCount Strong Buy0.0%0 ratings Buy45.8%11 ratings Hold45.8%11 ratings Sell8.3%2 ratingsOut of 24 total stock ratings issued by Asad Haider at The Goldman Sachs Group, the majority (45.8%) have been Buy recommendations, followed by 45.8% Hold and 8.3% Sell.Best & Worst CallsBest Call000.0%JNJApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%XRAYMar 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ54.5% of companies on NASDAQ6 companiesNYSE45.5% of companies on NYSE5 companiesAsad Haider, an analyst at The Goldman Sachs Group, currently covers 11 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical11 companies100.0%Asad Haider of The Goldman Sachs Group specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageLARGE CAP PHARMA5 companies45.5%MED - BIOMED/GENE4 companies36.4%MED - DRUGS1 company9.1%MED/DENTAL - SUPP1 company9.1% Asad Haider's Ratings History at The Goldman Sachs Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsBNTXBioNTech3/11/2026Reiterated Rating$83.89Buy$0.0000.00% ROIRPRXRoyalty Pharma2/12/2026Reiterated Rating$44.12Buy$0.0000.00% ROIABBVAbbVie1/28/2026Reiterated Rating$221.71$223.00Neutral$0.0000.00% ROIJNJJohnson & Johnson1/22/2026Reiterated Rating$218.12$250.00Buy$0.0000.00% ROIBNTXBioNTech1/16/2026Upgrade$106.07$142.00Buy$0.0000.00% ROIJNJJohnson & Johnson12/18/2025Boost Price Target$210.50$240.00Buy$0.0000.00% ROIBMYBristol Myers Squibb12/2/2025Reiterated Rating$49.14$57.00Neutral$0.0000.00% ROINAMSNewAmsterdam Pharma12/2/2025Boost Price Target$39.61$37.00Neutral$0.0000.00% ROIPFEPfizer11/5/2025Reiterated Rating$24.29$26.00Neutral$0.0000.00% ROIJNJJohnson & Johnson10/9/2025Boost Price Target$190.66$212.00Buy$0.0000.00% ROIINVAInnoviva9/30/2025Initiated Coverage$19.03$17.00Sell$0.0000.00% ROIRPRXRoyalty Pharma9/30/2025Initiated Coverage$35.25$42.00Buy$0.0000.00% ROIINVAInnoviva9/30/2025Initiated Coverage$18.17$17.00Sell$0.0000.00% ROIRPRXRoyalty Pharma9/30/2025Initiated Coverage$36.32$42.00Buy$0.0000.00% ROIPCVXVaxcyte9/12/2025Initiated Coverage$33.06$38.00Neutral$0.0000.00% ROINAMSNewAmsterdam Pharma7/17/2025Initiated Coverage$20.92$27.00Neutral$0.0000.00% ROIBNTXBioNTech5/29/2025Initiated Coverage$97.53$110.00Neutral$0.0000.00% ROIJNJJohnson & Johnson4/9/2025Upgrade$149.24$172.00Buy$000.0000.00% ROILLYEli Lilly and Company4/8/2025Upgrade$738.53$888.00Buy$000.0000.00% ROIABBVAbbVie4/8/2025Reiterated Rating$183.12$194.00Neutral$000.0000.00% ROIPFEPfizer4/8/2025Reiterated Rating$22.12$25.00Neutral$00.0000.00% ROIBMYBristol Myers Squibb4/8/2025Reiterated Rating$53.94$55.00Neutral$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageRoyal Bank Of CanadaJPMorgan Chase & Co.Berenberg BankWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyJefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
